Gregg Russo - BeyondSpring Senior Resources
| BYSI Stock | USD 1.74 0.03 1.75% |
Executive
Gregg Russo is Senior Resources of BeyondSpring
| Address | 100 Campus Drive, Florham Park, NJ, United States, 07932 |
| Phone | (646) 305-6387 |
| Web | https://beyondspringpharma.com |
BeyondSpring Management Efficiency
The company has return on total asset (ROA) of (0.3964) % which means that it has lost $0.3964 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1048) %, meaning that it created substantial loss on money invested by shareholders. BeyondSpring's management efficiency ratios could be used to measure how well BeyondSpring manages its routine affairs as well as how well it operates its assets and liabilities. The BeyondSpring's current Return On Equity is estimated to increase to 0.82, while Return On Tangible Assets are projected to decrease to (0.89). As of now, BeyondSpring's Total Assets are increasing as compared to previous years. The BeyondSpring's current Other Current Assets is estimated to increase to about 10.9 M, while Net Tangible Assets are projected to decrease to under 24.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dario MD | Eyepoint Pharmaceuticals | 67 | |
| Heather Boussios | Mink Therapeutics | N/A | |
| David House | Armata Pharmaceuticals | N/A | |
| BBA FCA | Oncolytics Biotech | N/A | |
| Wayne MBA | Oncolytics Biotech | 69 | |
| PMP PEng | Oncolytics Biotech | N/A | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Dolly Tyan | Aditxt Inc | N/A | |
| Ugo Perlingieri | Allovir | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Ramiro MD | Eyepoint Pharmaceuticals | 41 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Chase JD | Oncternal Therapeutics | 42 | |
| Robert Francomano | Sellas Life Sciences | 57 | |
| JD Esq | Kineta Inc | 50 | |
| Lisa MD | Seres Therapeutics | 65 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| MS MD | Armata Pharmaceuticals | 49 | |
| David MA | Eyepoint Pharmaceuticals | 57 | |
| Amy Levin | Oncolytics Biotech | N/A | |
Management Performance
| Return On Equity | -3.1 | ||||
| Return On Asset | -0.4 |
BeyondSpring Leadership Team
Elected by the shareholders, the BeyondSpring's board of directors comprises two types of representatives: BeyondSpring inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BeyondSpring. The board's role is to monitor BeyondSpring's management team and ensure that shareholders' interests are well served. BeyondSpring's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BeyondSpring's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth Lloyd, Chief Officer | ||
| Gregg Russo, Senior Resources | ||
| Stephen Kilmer, Head Relations | ||
| June Lu, Chief Officer | ||
| Linqing Jia, CoFounder | ||
| Ramon Mohanlal, Chief RD | ||
| Lan Huang, Chairman CoFounder |
BeyondSpring Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BeyondSpring a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.1 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (7.42) % | ||||
| Current Valuation | 58.24 M | ||||
| Shares Outstanding | 40.3 M | ||||
| Shares Owned By Insiders | 25.53 % | ||||
| Shares Owned By Institutions | 13.79 % | ||||
| Number Of Shares Shorted | 2.09 M | ||||
| Price To Earning | (8.63) X | ||||
| Price To Book | 5.38 X |
Currently Active Assets on Macroaxis
When determining whether BeyondSpring offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BeyondSpring's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Beyondspring Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Beyondspring Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeyondSpring. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in BeyondSpring Stock please use our How to Invest in BeyondSpring guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeyondSpring. If investors know BeyondSpring will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeyondSpring listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.40) | Revenue Per Share 0.048 | Quarterly Revenue Growth 0.143 | Return On Assets (0.40) | Return On Equity (3.10) |
The market value of BeyondSpring is measured differently than its book value, which is the value of BeyondSpring that is recorded on the company's balance sheet. Investors also form their own opinion of BeyondSpring's value that differs from its market value or its book value, called intrinsic value, which is BeyondSpring's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeyondSpring's market value can be influenced by many factors that don't directly affect BeyondSpring's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BeyondSpring's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeyondSpring is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeyondSpring's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.